Top Factor Driving Oral Proteins And Peptides Market Growth in 2025: Growing Biopharmaceutical Industry

What combination of drivers is leading to accelerated growth in the oral proteins and peptides market?
The expansion of the biopharmaceutical industry is forecasted to fuel the growth of the market for oral proteins and peptides. The biopharmaceutical industry operates within the larger pharmaceutical industry and specializes in the creation, production, and marketing of medication sourced from biological materials. Growth within the biopharmaceutical sector can be attributed to advancements in biotechnology, a surge in the demand for personalized medication, an increasing occurrence of chronic ailments, and significant investment in research and development. Oral proteins and peptides in biopharmaceuticals have the potential for non-invasive therapeutic delivery, thereby enhancing patient adherence and lessening the necessity for injections. They also exhibit improved stability and absorption in the digestive system, thus targeting specific diseases. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade group that represents the pharmaceutical industry, reported in June 2023 that the total biopharmaceutical production in Europe for 2022 was valued at $384,200 million (€340,000 million), a nearly 4.95% increase on the 2021's total of $366,267 million (€323,950 million). Consequently, the escalating biopharmaceutical industry is bolstering the growth of the oral proteins and peptides market.

Get Your Oral Proteins And Peptides Market Report Here:
https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

What is the projected compound annual growth rate (CAGR) of the oral proteins and peptides market from 2025 to 2034, and what factors influence it?
The market size for oral proteins and peptides has experienced exceptional growth in the past few years. Its market value is predicted to increase from $1.27 billion in 2024 to $1.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 22.7%. The substantial growth observed in the past is attributed to several factors including the increasing incidence of chronic diseases, growing investments in the biotechnology sector for creating oral protein-based therapies, rising consumer inclination towards non-invasive treatment methods, expansion in the biopharmaceutical industry, and the escalating focus on personalized medicine.

The market size for oral proteins and peptides is predicted to experience substantial growth in the upcoming years, reaching a value of $3.49 billion in 2029 with a compound annual growth rate (CAGR) of 22.3%. This growth is expected due to various factors such as an increasing emphasis on patient-focused medications, a growing elderly population, escalating healthcare costs, the urgent need for cancer diagnostics, and a rising preference for orally administered medications. Key trends projected for the period include the creation of innovative oral peptides with improved stability and effectiveness, the application of artificial intelligence in the drug discovery process for oral formulations, progressed medical treatments, advancements in drug delivery technologies, and innovative oral insulin formulations.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

How are the latest trends influencing the growth of the oral proteins and peptides market?
Significant players in the market for oral proteins and peptides are concentrating on the development of novel items like Oral Semaglutide to improve patient compliance and comfort. Oral semaglutide presents a significant milestone in the advancement of oral proteins and peptides. Commonly delivered via injection to manage type 2 diabetes and recently obesity, Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, had an impressive advancement with its oral form. Novo Nordisk India, a healthcare company based in India, launched the first oral semaglutide in the world in January 2022, marking a significant progression in the treatment of diabetes. Formerly only available in injectable form, Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), now provides a more convenient oral method for managing type 2 diabetes. This development not only revolutionizes how we treat diabetes, but also provides a platform for future advancements in oral insulin formulation potentially ushering in more effective and patient-preferred therapy options.

What are the major segments of the oral proteins and peptides market and their role in driving growth?
The oral proteins and peptidesmarket covered in this report is segmented -

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629

What regions are at the forefront of oral proteins and peptides market expansion?
North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the oral proteins and peptides market?
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

What Is Covered In The Oral Proteins And Peptides Global Market Report?

•Market Size Forecast: Examine the oral proteins and peptides market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the oral proteins and peptides market for a structured understanding.
•Key Players Overview: Analyze major players in the oral proteins and peptides market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the oral proteins and peptides market.
•Segment Contributions: Evaluate how different segments drive overall growth in the oral proteins and peptides market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the oral proteins and peptides market.
•Industry Challenges: Identify potential risks and obstacles affecting the oral proteins and peptides market.
•Competitive Landscape: Review strategic developments in the oral proteins and peptides market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.